~~<i id='A13C2C6684'><strike id='A13C2C6684'><tt id='A13C2C6684'><pre id='A13C2C6684'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：knowledge 2025-08-08 05:32:53 - browse：12386

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Lasker Awards 2023: Winners in biomedical research

focus

entertainment

hotspot

leisure time

AdobeTravereTherapeuticssaidThursdaythatastudymeanttoconfirmthebenefitofitsnewlyapproveddrugforarare

WSS

Studies point to risks of excluding people with obesity from drug trials

Emergency workers more likely to restrain Black patients: study

Senate committee scrutinizes Medicare Advantage brokers

STAT Summit: Michael J. Fox on progress in Parkinson's research

CEOs share strategies for surviving biotech slump

EpiPen alternative approval delay highlights citizen petition issue

focus

hotspot

focus

How to save PrEP access — and even expand it

Will Ozempic

What does generative AI mean for health care? We asked experts

Experts study whether long Covid risk adds up with each reinfection

Medicare proposal to cover medical devices draws a mixed reaction

Hearing on Medicare drug price negotiation gets unusually heated

Affirmative action in medical school literally saved lives

Hearing on Medicare drug price negotiation gets unusually heated

Malaria cases in Florida and Texas: Here’s what you need to know

FDA gives detailed accounting of AI

focus

UnitedHealth’s board chair also owns a personal investment firm

Senators: Long

The explosion of genetic testing requires a new approach

Why health workers in Gaza are injured or die at high rates

STAT Summit: GSK CEO on pharma giant's new direction

2023 STAT Wunderkinds: get to know the winners

entertainment

hotspot

hotspot

leisure time